XORTX Therapeutics Targets $700M Gout Market with XORLO
XORTX Therapeutics advances XORLO, a novel gout treatment, with manufacturing and FDA plans. Could capture $700M market as gout cases rise globally.
With gout cases projected to skyrocket and current treatments often intolerable, XORTX's XORLO could offer a safer, more effective alternative that improves patient adherence and quality of life. If approved, it would address a critical gap in care for millions suffering from this debilitating disease, potentially reducing healthcare costs and lost productivity while providing a much-needed option for those who cannot tolerate existing therapies.
